According to the Centers for Disease Control and Prevention (CDC), the US government will allocate approximately 85% fewer doses of Johnson & Johnson’s Covid-19 vaccine to states next week due to uneven production, partly a result of issues at a Baltimore manufacturing facility. The week’s allocation is expected to drop to 785,500 doses from 4.95 million doses, although this data does not include allocations to a federal retail pharmacy programme.
Eli Lilly and Incyte have announced results from the Phase III COV-BARRIER study of baricitinib 4mg for treating hospitalised Covid-19 patients. The study did not meet statistical significance in 1,525 patients, although data revealed a 38% fall in deaths by the 28th day among patients treated with baricitinib along with standard-of-care treatment, including corticosteroids and/or remdesivir. Patients receiving baricitinib were 2.7% less likely to progress to ventilation or death, a difference that was not statistically significant.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The Institute of Public Health of Chile has granted emergency use approval to CanSinoBIO’s single-dose Covid-19 recombinant vaccine, Convidecia. It is the first single-dose vaccine to be approved for emergency use in Chile, and the first approval of Convidecia in South America. Interim Phase III trial results suggest the vaccine is 65.28% effective at preventing symptomatic Covid-19 28 days after dosing, with an efficacy rate of 90.07% in preventing severe illness 28 days after the single-dose vaccination.
